Procept Biorobotics Corp Cash Flow Conversion Efficiency
Procept Biorobotics Corp cash flow conversion efficiency. Based on the latest financial reports, Procept Biorobotics Corp (PRCT) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.63 Million) by net assets ($380.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Procept Biorobotics Corp (2019–2024)
Cash flow conversion efficiency of Procept Biorobotics Corp from 2019 to 2024. This chart illustrates how Procept Biorobotics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Procept Biorobotics Corp stock price for real-time trading data and today's change.
Procept Biorobotics Corp Cash Flow Conversion Ratio Explained
Procept Biorobotics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Procept Biorobotics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procept Biorobotics Corp ranked by their cash flow conversion efficiency. Also see market cap of Procept Biorobotics Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ramsay Generale De Sante
PA:GDS
|
0.060x |
|
Mahanagar Gas Limited
NSE:MGL
|
0.083x |
|
Vohringer Home Technology Co Ltd
SHG:603226
|
0.014x |
|
Fox-Wizel Ltd
TA:FOX
|
0.018x |
|
NTG Nordic Transport Group A/S
CO:NTG
|
-0.002x |
|
Genting Plantations Bhd
KLSE:2291
|
0.000x |
|
Aker Biomarine AS
OL:AKBM
|
-0.046x |
|
Wuhan East Lake High Technology Group Co Ltd
SHG:600133
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Procept Biorobotics Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Procept Biorobotics Corp from 2019 to 2024. Review financial flexibility index of Procept Biorobotics Corp to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $402.22 Million | $-99.21 Million | -0.247x | +35.88% |
| 2023-12-31 | $280.75 Million | $-108.00 Million | -0.385x | +5.69% |
| 2022-12-31 | $197.07 Million | $-80.38 Million | -0.408x | -90.01% |
| 2021-12-31 | $267.09 Million | $-57.33 Million | -0.215x | +72.93% |
| 2020-12-31 | $60.96 Million | $-48.34 Million | -0.793x | +47.10% |
| 2019-12-31 | $29.23 Million | $-43.82 Million | -1.499x | -- |
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Rob… Read more